Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

Item

http://www.wikidata.org/entity/Q38029953

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

@en

type

Item

label

Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

@en

prefLabel

Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

@en

P1476

Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

@en

P2093

Md Pazil Aqilah

http://www.w3.org/2001/XMLSchema#string

S Abdul Wahid Fadilah

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the intensity of conditioning regimens: working definitions

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.

Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy.

Mixed chimerism: preclinical studies and clinical applications.

Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.

Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.

P2888

s12015-012-9401-8

P304

1254-1264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12015-012-9401-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1000446653

http://www.w3.org/2001/XMLSchema#string

P698

22836809

http://www.w3.org/2001/XMLSchema#string